Σάββατο 2 Απριλίου 2016

What Is Trichotillomania? And How Is It Treated?


Bret S. Stetka, MD; Lindsey M. Muller, MS

|April 30, 2015

Editor's Note: In her new book Life Is Trichy: Memoir of a Mental Health Therapist With a Mental Health Disorder, behavioral therapist Lindsey M. Muller, MS, writes about her own struggles with trichotillomania, a condition in which patients uncontrollably pull out their hair. The disorder is more common than you might think, and Medscape recently interviewed Ms Muller on what exactly trichotillomania is and how to manage it. 

Background

Medscape: What is trichotillomania? 

Ms Muller: According to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), the symptoms of trichotillomania are:

  • Recurrent pulling out of one's hair, resulting in hair loss;

  • Repeated attempts to decrease or stop hair-pulling;

  • The hair-pulling causes clinically significant distress or impairment in social, occupational, or other important areas of functioning;

  • The hair-pulling or hair loss is not attributable to another medical condition (eg, a dermatologic condition); and

  • The hair-pulling is not better explained by the symptoms of another mental disorder (eg, attempts to improve a perceived defect or flaw in appearance in body dysmorphic disorder).

Medscape: Can you briefly review the history of the condition? When was it first described, and how has understanding of it has evolved over the years?

Ms Muller: The name of the disorder was coined by French dermatologist François Hallopeau in 1889 and comes from the Greek words trich (hair), tillein (to pull), and mania (madness). However, the disorder was not formally introduced as a disorder and added to the DSM-III-R until 1987.

Classification of the disorder has been vague and questioned by many researchers and clinicians; it has been conceptualized as an obsessive-compulsive spectrum disorder, anxiety disorder, and an impulse control disorder, and most recently it appears under "Obsessive-Compulsive and Related Disorders" in DSM-5. The understanding of the disorder as sometimes present without reported feelings of anxiety and with inclusion of a sensory processing component has greatly altered how the disorder is presented in various DSM versions. From the DSM-IV-TR to the DSM-5, the following changes were made:

  • Trichotillomania moved from the impulse control disorder category to the obsessive-compulsive and related disorders category;

  • Criterion B, "an increasing sense of tension immediately before pulling out the hair or when attempting to resist the behavior" was removed; and

  • Criterion C, "pleasure, gratification, or relief when pulling out the hair" was also removed.

Medscape: Whom does trichotillomania affect, and how widely?

Ms Muller: The lifetime prevalence of trichotillomania is estimated to be between 1% and 4% of the overall population. It is expected that this percentage is probably higher owing to the shame and stigma associated with the disorder. Even with increased research and media exposure to shed light on this disorder, many people are still unaware that there is a name for the behavior of hair-pulling.

With regard to gender distribution, the female-to-male ratio is 3 to 1. Again, this statistic is questionable, given that men may underreport symptoms because they shave to "manage" the behavior.

Causes and Treatment

Medscape: Do we know anything about what causes trichotillomania? Are there associated risk factors?

Ms Muller: The etiology of trichotillomania is still unknown. However, we do know there are various factors to consider. Neurobiological research via brain scans demonstrates the structure and functioning of persons with trichotillomania to differ from that of control participants, persons with attention-deficit/hyperactivity disorder (ADHD), persons with tic disorder, and persons with obsessive-compulsive disorder (OCD). There is a genetic component in some cases; we have identified families in which trichotillomania is diagnosed in parent and child, or siblings.

Personality traits (low tolerance to stress, perfectionism, low tolerance to anxiety) are apparent. Sensory processing, such as overstimulation or understimulation from an environmental or physical standpoint, is also relevant when discussing etiology. As in all other mental health disorders, there are exceptions. Additional areas of further research that have been reported include the relationship between pulling urges and sugar consumption, caffeine consumption, and lack of sleep.

Risk factors include family history; age (peak onset is most often between age 11 and 13 years); poor coping mechanisms for emotional regulation; premorbid mental health diagnoses, such as ADHD, OCD, tic disorder, an eating disorder, an anxiety disorder, or depressive disorder; and the personality traits mentioned above.

Medscape: How is trichotillomania treated and managed?

Ms Muller: Empirically validated treatment for trichotillomania includes cognitive-behavioral therapy (CBT) and acceptance and commitment therapy (ACT), which is the third wave of treatment approaches and a branch of CBT. ACT teaches patients to recognize, accept, and embrace urges without acting on them. Behavioral approaches, such as habit reversal, stimulus control, and awareness training, are also used and are efficacious.

Regarding medication, research is not overwhelmingly positive on prescribing medication for trichotillomania. Some patients benefit from use of a selective serotonin reuptake inhibitor in conjunction with psychotherapy, whereas others do not.

There is no cure for trichotillomania, but freedom from it is possible by recognizing the behavior, increasing awareness of the thoughts and feelings driving the urges, understanding that urges are different from behaviors, breaking the habitual cycle of pulling with behavioral interventions, increasing positive coping skills, and incorporating sensory regulation methods.

A Personal Account

Medscape: If you are comfortable doing so, can you tell us a bit about your own struggle with the condition?

Ms Muller: I started with skin-picking and nail-biting from a young age (approximately 4). Over time, these behaviors subsided, and I began pulling my hair in seventh grade until 2008 (when I was 24 years old). It was a daily and constant struggle as I tried to fight the urges day after day. Each time, I would lose the fight. The more I focused on not pulling, the more I pulled.

I tried CBT, many medications, hypnosis, and wearing something on my head at all times. Each tactic seemed to work in the beginning (the placebo effect), but the results never lasted. It was frustrating and disheartening. I felt alone, ashamed, guilty, damaged, and lost.

In 2008, I found freedom from hair-pulling when I came to understand that pulling was a choice. I could not choose whether or not I had an urge, but I could choose what to do with that urge. I waited several years until I felt enough distance and separation from my own struggle before I opened my doors to patients.

Medscape: Do you have any final thoughts for a clinician audience on how to approach this condition and discuss it with their patients?

Ms Muller: For clinicians who may not be familiar with treatment of trichotillomania, it is important to recognize that this disorder is not treated like OCD, but requires specialized understanding and treatment approaches.

And for all clinicians, I would like to share that trichotillomania is almost always a symptom of something else. Treating the behavior as "just a behavior, or just a habit" is not going to address what is underlying the behavior. To really make progress, the following questions should be explored and answered: "What is driving the urges? Where are they coming from?" When treating patients, I tend to view trichotillomania as a messenger or a red flag that something is out of alignment or has gone awry.

Finally, patients may get worse before they get better as personal experiences, deep-rooted emotions, and core beliefs are brought to the surface.

Σάββατο 5 Μαρτίου 2016

Celiac Disease: Which Children Should Be Tested?

For Ritu Verma, MBChB, director of the Center for Celiac Disease and the Lustgarten Endowed Chair for Clinical Care of GI Motility Disorders at the Children's Hospital of Philadelphia in Pennsylvania, those numbers and the consequences of undiagnosed CD lead to a straightforward conclusion: "The biggest plea I have for pediatricians is to just do the panel," she told Medscape Medical News, referring to an antibody test panel that can help to determine whether a child likely has the disease.

However, other pediatric gastroenterologists, including Saeed Mohammad, MD, from Northwestern University Feinberg School of Medicine in Chicago, Illinois, feel that screening the entire population is just not feasible, and the cost of increased screening may not be justified.

"[CD] is more common in certain ethnic groups and less common in others," he told Medscape Medical News. "Unless the cost of genetic testing drastically decreases, I believe the current system of screening children with risk factors for [CD] such as diabetes, Down syndrome, or autoimmune diseases, as well as testing for celiac-specific antibodies in children whose growth is faltering [and] those who have diarrhea or chronic abdominal pain, is the most cost-effective option with the greatest sensitivity."

Moreover, he notes that children younger than 2 years should not be tested without high clinical suspicion, "and [diagnosis] should always be confirmed with endoscopy and biopsy," he continued.


Τρίτη 2 Φεβρουαρίου 2016

Antibiotic Eardrops Cost-Effective in Kids With Acute Tympanostomy-Tube Otorrhea



NEW YORK (Reuters Health) - For acute otorrhea in children with tympanostomy tubes, antibiotic-glucocorticoid eardrops are not only clinically superior to oral antibiotics and initial observation, they also cost less, according to a study published this week.
Last year in the New England Journal of Medicine, Dr. Thijs van Dongen of the University Medical Center Utrecht in the Netherlands and colleagues reported an open-label trial on the clinical effectiveness of these three treatment strategies in 230 children.
As reported by Reuters Health, one week after the end of treatment, only 5% of the 76 children who received the eardrops -- which contained hydrocortisone, bacitracin and colistin -- had otorrhea compared to 44% of the 77 youngsters given an oral amoxicillin-clavulanate suspension. The rate among the 77 children initially put in an observation group was 55%, which was not significantly different from the cure rate with the oral therapy.
In a study online April 20 in Pediatrics, the researchers report a cost-effectiveness analysis of the treatment strategies, which also favors eardrops.
At two weeks, the total cost in US dollars per patient on average was $42 for antibiotic-glucocorticoid eardrops, $71 for oral antibiotics and $82 for initial observation. At six months, these costs were $368, $421, and $640, respectively, the authors report.
Otorrhea is common in children with tympanostomy tubes; each year, two of every three children develop one or more episodes.
In an email to Reuters Health, Dr. van Dongen noted that the original clinical effectiveness data were "widely covered in the media. At that time, all three treatment strategies were commonly used and with our results we recommended to only use antibiotic-steroid eardrops as the first-line treatment strategy in children with acute tympanostomy-tube otorrhea. In the Netherlands, the guidelines have been adapted based on our results. We hope that through the wide coverage, many physicians now do prescribe eardrops and that clinical practice has already changed."
"With this new publication in Pediatrics, we have an extra argument in favor of starting with ear drops instead of with initial observation, i.e., it is not only clinically superior, it is also has lowest costs," Dr. van Dongen noted.
Dr. Charles Bower, chair of the American Academy of Pediatrics Section on Otolaryngology-Head and Neck Surgery, told Reuters Health there is not a guideline specific to post-tube otorrhea. "The guidelines from AAP deal more with acute otitis media," he noted.
In clinical practice, otolaryngologists "typically have the ability to clean ears, make sure tubes are open, make sure tubes are clean and they are fine, and we would virtually 100% of the time use drops alone," Dr. Bower said. "Pediatricians, if they are very confident from a recent visit that a tube is open and fine, will also frequently use drops alone, which has increased effectiveness as well as some cost savings. If a pediatrician has uncertainty, then we still see a fairly high addition of an oral antibiotic."
The study had no commercial funding and the authors have no relevant disclosures. Microbiological analyses of samples taken as part of the trial were supported by GlaxoSmithKline through the University Medical Center Utrecht.
SOURCE: http://bit.ly/1JqVcZm
Pediatrics 2015.

MMR Vaccine Not Linked to Autism, Even in High-Risk Kids


Receipt of the measles, mumps, and rubella (MMR) vaccine was not linked to an increased risk for autism spectrum disorder (ASD), even when older siblings had ASD, a new study shows.
"These findings indicate no harmful association between MMR vaccine receipt and ASD even among children already at higher risk for ASD," Anjali Jain, MD, from the Lewin Group, Falls Church, Virginia, and colleagues write. The researchers present their findings in an article published in the April 21 issue of JAMA.
The investigators used an administrative claims database (the Optum Research Database) connected with a large commercial health plan to conduct a retrospective cohort study. They included children who had been continuously enrolled in the health plan from birth until they were at least aged 5 years during 2001 to 2012. The children also must have had an older sibling who had been continuously enrolled in the health plan for 6 months or longer between 1997 and 2012.
The researchers categorized MMR vaccine exposure according to the number of doses (0, 1, or 2) received between birth and age 5 years.
The study's main outcomes and measures were ASD status, which the researchers defined as two medical claims with a diagnosis code at any point along the autistic disorder or other specified pervasive developmental disorder, including Asperger syndrome, or unspecified pervasive developmental disorder (International Classification of Diseases, Ninth Revision, Clinical Modification, 299.0x, 299.8x, 299.9x).
The researchers included 95,727 children with older siblings. Overall, 994 (1.04%) of those children were diagnosed with ASD and 1929 (2.01%) had an older sibling with ASD. Among the children who had older siblings with ASD, 134 (6.9%) were diagnosed with ASD compared with 860 (0.9%) who were diagnosed with ASD and did not have an affected sibling (P < .001).
The MMR vaccination rate (≥1 dose) for those with siblings without ASD was 84% (n = 78,564) at age 2 years and 92% (n = 86,063) at age 5 years.
MMR vaccination rates were lower for those with older siblings with ASD at age 2 years (73% [n = 1409]) and 5 years (86% [n = 1660]).
The researchers adjusted for potential confounders, including sex of the index child, mother's and father's age at index child's birth, geographic location defined by the four US Census regions, mental health benefits, and index child birth year, which the researchers included to adjust for varying opportunities for ASD to develop or be diagnosed.
Receipt of MMR vaccination was not linked to a higher risk for ASD at any age.
For those with older siblings with ASD, at age 2 years, the adjusted relative risk (RR) for ASD for a single dose of MMR vaccine compared with no vaccine was 0.76 (95% confidence interval [CI], 0.49 - 1.18; P = .22), and at age 5 years, the RR of ASD for 2 doses compared with no vaccine was 0.56 (95% CI, 0.31-1.01; P = .052).
For those with older siblings without ASD, at age 2 years, the adjusted RR for ASD for a single MMR vaccine dose was 0.91 (95% CI, 0.67 - 1.20; P = .50), and at age 5 years, the adjusted RR for ASD for two vaccine doses was 1.12 (95% CI, 0.78 - 1.59; P = .55).
The cause or causes of autism have been difficult to identify, writes Bryan H. King, MD, MBA, from the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, and Seattle Children's Hospital, Washington, in an accompanying editorial.
"More recently, controversy continues and is reflected in changes in diagnostic criteria and the increasing recognition of heterogeneity that incorporates the word 'spectrum' into the diagnosis," Dr King writes. "With each new prevalence estimate that suggests inexplicable and substantial increases in the number of children diagnosed with the disorder, the urgency to better understand causation is amplified."
Some parents of children with ASD have chosen to put off immunization of later children until they were sure the risk for ASD had passed, Dr King writes.
"Such behavior, which arguably could enrich the immunization rate in the nonautism subgroup relative to the group that may have been showing early atypical development, might create the impression that MMR vaccine is actually reducing risk for ASD. Indeed, Jain et al report relative risks of less than 1.0." Dr King explains. "Even so, short of arguing that MMR vaccine actually reduces the risk of ASD in those who were immunized by age 2 years, the only conclusion that can be drawn from the study is that there is no signal to suggest a relationship between MMR and the development of autism in children with or without a sibling who has autism."
This study was funded by the National Institute of Mental Health, National Institutes of Health, and the US Department of Health and Human Services. Dr Jain and two coauthors report being employees of the Lewin Group. Two coauthors are employees of Optum, which a wholly owned subsidiary of UnitedHealth Group. The Lewin Group is an Optum company. The Lewin Group operates with editorial independence. The other authors and Dr King have disclosed no relevant financial relationships.
JAMA. 2015;313:1518-1519, 1534-1540.

Care Needed to Reduce Pet-to-Human Infection Risk


By Kathryn Doyle
(Reuters Health) - Pets can be a source of infection, and newborns, the elderly, children with leukemia and adults with cancer are especially vulnerable, according to a new review of data from previous research.
Selecting the right pets and using safe strategies to care for them can reduce the risk, the authors write.
"Pets have a number of really important health benefits," including emotional and social support, said lead author Dr. Jason Stull of the Department of Veterinary Preventive Medicine at Ohio State University in Columbus.
And actually contracting an infection from a pet is relatively uncommon, he and his colleagues say.
"The biggest issue comes down to really recognizing when individuals are at greater risk," Stull said.
People with compromised immune systems are at increased risk for these infections and may have more severe disease, the authors write. Also at increased risk are kids under age five, adults over age 65, and pregnant women.
Pet-sourced infections have also been reported in organ donors and recipients, according to Bruno Chomel, who researches veterinary public health and zoonoses at University of California, Davis School of Veterinary Medicine. Chomel was not part of the new review.
More than half of households in the U.S. have pets, Chomel noted.
"We are not saying that you should get rid of the pet," he told Reuters Health by phone. But if your immune system is compromised, he added, "don't take in a stray pet or a kitten with fleas, and if you have young toddlers, don't take an iguana as a pet."
Many people don't realize their pets can be a source of infection, Stull told Reuters Health by phone.
Reptiles, amphibians, hedgehogs, chinchillas, rodents and young chickens are some of the "highest risk" animals, he said.
There aren't good data on actual rates of so-called zoonotic infections, because governments don't generally track diseases transmitted by companion animals, other than rabies.
But pets can theoretically transmit more than 70 human diseases via bites, scratches and contact with body fluids (such as saliva, urine, or feces, or infectious aerosols or droplets), the authors write online April 20 in CMAJ.
The new review covered more than 300 articles on infections originating in companion animals. Most of the studies were small, the authors note. The review also included guidelines developed by other experts.
Cats are the definitive host for the parasite Toxoplasma gondii, which can lead to congenital defects, encephalitis or meningitis when a pregnant woman is exposed.
"Your risk of toxoplasma is much higher from gardening or eating undercooked meat," Stull noted.
But in any case, it seems that neither doctors nor veterinarians are asking their human clients about pets or about young children, elderly people, or other vulnerable family members in the home.
"Most patients do not ever recall being asked if they have pets," Stull said.
When a child is diagnosed with cancer, the family may go out and get a new pet to help cope.
"In most situations there are options for finding a pet for that household, but it requires having a conversation with physicians and veterinarians," Stull said.
"It really requires strong integration and communication between all of these different groups," he said.
The most frequent mode of transmission is fecal-oral, Stull said, and care strategies can minimize that risk.
He and his coauthors recommend wearing protective gloves to clean aquariums and cages and remove feces, proper handwashing after pet contact, discouraging pets from face licking, covering playground boxes when not in use, avoiding contact with exotic animals, regular cleaning and disinfection of animal cages, feeding areas and bedding, locating litter boxes away from areas where eating and food preparation occur and regularly scheduling veterinary visits for all pets.
Households with immunocompromised people or very young children (under a few months of age) should avoid contact with puppies and kittens that are younger than six months, and avoid adopting a cat younger than a year old, the authors suggest. These people should also avoid young farm animals at petting zoos.
"Other practices will be important for all children under five years, such as strict hand washing and ensuring pets are healthy and receive preventive veterinary care," Stull said.
"There isn't necessarily one 'safest' animal, but mature dogs and cats who are well cared for are a lower risk," he said.
It is also important to teach children how to interact with pets to minimize the risk of bites, Stull added.
Many people today treat pets as children, and allow the pets to lick them and sleep in their beds, Chomel said.
"If pets are healthy, the risk is low, but your dog and cats walk outside and they bring things back," he said.
SOURCE: http://bit.ly/1zDd8KW
CMAJ 2015.

Preventing Celiac Disease in Infants: The Known and Unknown


Ritu Verma, MD
|April 13, 2015
Hi, I'm Ritu Verma. I'm one of the pediatric gastroenterologists at the Children's Hospital in Philadelphia, and I'm the director of the Celiac Center.
Today, I would like to provide some updates about celiac disease. As you know, celiac disease is an autoimmune condition, and it's the result of certain genetic factors and eating gluten. However, we do know that there are some people who have these specific genes, eat gluten-containing foods, and do not get the disease. There has been a lot of discussion about what these other factors are that actually cause the disease to be manifested.
One of the big concerns and questions in the past has been about actual nutritional input for these babies, in terms of when do we introduce gluten. Does it really make a difference in onset of the disease or the severity of the disease?
In the past, studies have found that introducing gluten between 4 and 6 months of age—not too early in life, and not too late in life—and breastfeeding at the same time seems to have been protective. We've recommended in the past that children who are genetically susceptible to celiac disease be fed cereal between those 4 to 6 months of age.
Recently, however, there were two large studies[1,2] from Europe that followed genetically susceptible babies and their eating patterns over time. It seemed that it did not make a difference whether these babies were given cereal early or late in the first year of life. It did not seem to make a difference whether they were being breastfed or not. This is definitely contrary to what we've been discussing so far with our patients.
What was also found as part of the studies was that the genetic types seem to be the more important factor. Babies who were HLA DQ2 homozygous-positive had earlier onset of the disease. Once again, it did not seem to make a difference when the cereal or gluten were introduced.
Currently, what we are recommending is to have babies and moms and dads follow the guidelines[3] by the American Academy of Pediatrics (AAP) in terms of when to introduce cereals and foods. We totally agree that breastfeeding is important for the babies. This has been confusing. However, this is what we have currently.
These questions are just like, for example, those raised by the Learning Early About Peanut Allergy (LEAP) study,[4] whose results were published earlier this year. Initially, we were always taught that peanuts should be introduced later in life to cut down on peanut allergies. The recent study indicates that introducing peanuts early in the diet seems to cut down on peanut allergies in life.
A lot of confusion; however, this is the update, currently, for celiac disease. As we have more research and more long-term studies being done, we will bring those back to you as well. Thank you.

References

  1. Aronsson CA, Lee HS, Liu E, et al; TEDDY Study Group. Age at gluten introduction and risk of celiac disease. Pediatrics. 2015;135:239-245. http://pediatrics.aappublications.org/content/early/2015/01/13/peds.2014-1787.full.pdf+html Accessed April 1, 2015.

Δευτέρα 15 Ιουνίου 2015

Celiac Disease: Which Children Should Be Tested?


Lara C. Pullen, PhD
March 23, 2015
Serological screening studies indicate that celiac disease (CD) has a prevalence of 1% to 2% in Western populations and that the incidence is increasing across all age groups. Although many individuals develop symptomatic CD, others do not. In fact, researchers estimate that just 10% to 30% of patients with CD are ever diagnosed, in part because they may be asymptomatic.
For children, that lack of diagnosis can be critical: Young children with undiagnosed CD are particularly vulnerable to the effects of malabsorption and failure to thrive.
Because of that danger, some researchers and clinicians are pushing for widespread screening. Some experts go even further, suggesting that the entire pediatric population should be routinely screened for CD. Yet the cost and the need for invasive confirmatory biopsies leave others skeptical of that approach unless better, cheaper diagnostics become available
New data published in the March issue of the American Journal of Gastroenterology by Rok Seon Choung, MD, PhD, from the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, and colleagues, show that among a representative sample of nearly 15,000 Americans aged 6 years or older, the prevalence of confirmed CD was 0.8% (95% confidence interval [CI], 0.5% - 1.0%) in 2009 to 2012.
Extrapolating to the population at large, the data suggest that more than 1.5 million people in the United States have CD. Moreover, the analysis showed a near doubling in the prevalence among adults aged 50 years or older, rising from 0.17% (95% CI, 0.03 - 0.33%) in the 1988 to 1994 National Health and Nutrition Examination Survey to 0.44% (95% CI, 0.24% 0 0.81%) in the 2009 to 2012 survey. However, the adjusted prevalence is uneven among racial and ethnic groups, ranging from 1.0% of whites to 0.2% of blacks and 0.3% of Hispanics.
For Ritu Verma, MBChB, director of the Center for Celiac Disease and the Lustgarten Endowed Chair for Clinical Care of GI Motility Disorders at the Children's Hospital of Philadelphia in Pennsylvania, those numbers and the consequences of undiagnosed CD lead to a straightforward conclusion: "The biggest plea I have for pediatricians is to just do the panel," she told Medscape Medical News, referring to an antibody test panel that can help to determine whether a child likely has the disease.
However, other pediatric gastroenterologists, including Saeed Mohammad, MD, from Northwestern University Feinberg School of Medicine in Chicago, Illinois, feel that screening the entire population is just not feasible, and the cost of increased screening may not be justified.
"[CD] is more common in certain ethnic groups and less common in others," he told Medscape Medical News. "Unless the cost of genetic testing drastically decreases, I believe the current system of screening children with risk factors for [CD] such as diabetes, Down syndrome, or autoimmune diseases, as well as testing for celiac-specific antibodies in children whose growth is faltering [and] those who have diarrhea or chronic abdominal pain, is the most cost-effective option with the greatest sensitivity."
Moreover, he notes that children younger than 2 years should not be tested without high clinical suspicion, "and [diagnosis] should always be confirmed with endoscopy and biopsy," he continued.
When and How to Test?
Classic symptoms of CD include prolonged abdominal pain, poor growth, chronic diarrhea, and abdominal distention. When children present with these symptoms, physicians may think of testing for CD, but unfortunately, there is no standardized celiac panel.
The Children's Hospital of Philadelphia, where Dr Verma practices, recommends a screening panel that includes total immunoglobulin A (IgA), antitransglutaminase (anti-tTG), and antiendomysial. Deaminated gliadin can be ordered in conjunction with anti-tTG. In addition, for children younger than 3 years, it may be advisable to test for antigliadin, she says.
Dr Verma would prefer that all children be screened for CD, but if that is not possible, then she encourages pediatricians to screen when they have even the slightest suspicion that the child might have CD.
She notes that many children who are diagnosed with CD in her clinic do not have a classic presentation. Thus, Dr Verma actively educates primary care physicians about CD and encourages them to consider the possibility of CD if they are treating a patient who does not seem to get better. The primary care physician can then order the simple celiac blood test.
Meanwhile, Boston Children's Hospital in Massachusetts focuses their screening efforts on high-risk children. These would be children with classic symptoms of CD such as abdominal pain and chronic diarrhea, as well as those at known genetic risk for CD and children with type 1 diabetes.
Boston Children's Hospital uses a similar celiac panel to the one used by the Children's Hospital of Philadelphia. "We recommend that 'high-risk' children be screened with serologic celiac tests (specifically tissue transglutaminase IgA and a total IgA), even if they have no identifiable symptoms," Dascha C. Weir, MD, associate director of the Celiac Program at Boston Children's Hospital in Massachusetts, told Medscape Medical News.
A child who is strongly positive for all of these antibody tests likely has CD.
Dr Verma acknowledges that the tests can give false-negatives and provide a false sense of security to parents. They can also give a false-positive. This is why the definitive test for CD is upper endoscopy.
Dr Verma explained that physicians also need to take a dietary history. Some children do not eat a lot of gluten between the ages of 2 and 3 years, and therefore may not test positive on the celiac panel. Unfortunately, most pediatricians do not have the time to take a complete dietary history.
Moreover, the United States has a heterogeneous population, and some experts suggest that a one-size-fits-all screening approach may not be practical. That said, "care providers should have a low threshold to order celiac testing for children with gastrointestinal symptoms or nongastrointestinal symptoms," Dr Weir emphasized.
Classic Symptoms Inadequate Cues
Regrettably, many primary care physicians have the false impression that children who lack classic symptoms of CD should not be screened for the disease. Unfortunately, relying on symptoms to trigger CD testing could miss a substantial proportion of affected children, according to recently published data from Sweden.
Daniel Agardh, MD, PhD, from Lund University in Sweden, and colleagues published their subanalysis of data from The Environmental Determinants of Diabetes in the Young (TEDDY) study online March 2 in Pediatrics. Whereas the primary goal of TEDDY is to identify genetic and environmental factors that contribute to the development of type 1 diabetes, Dr Agardh and colleagues used the birth cohort data to compare children who were positive for anti-tTGA with those who were negative for anti-tTGA.
They found that, compared with children who were negative for anti-tTGA, children positive for anti-tTGA were more likely to be symptomatic at 2 and 3 years of age, but not at 4 years of age. In addition, the researchers report that anti-tTGA levels correlate with severity of mucosal lesion in symptomatic and asymptomatic children, and some asymptomatic children had quite elevated levels of anti-tTGA. These children were diagnosed with CD because they were enrolled in the study, but likely would have been missed in standard practice.
Results from the study have led the experts to propose a two-tiered screening system by which all newborns are first specifically screened for genetic susceptibility such as HLA type and, if positive, then screened for celiac-specific antibodies. This screening protocol would be a departure from that used in the United States and would include much more comprehensive genetic screening.
"With awareness and availability of gluten-free foods increasingly entrenched within the mainstream of the North American lifestyle, the burden lies on the identification of all children who may benefit from treatment. The prospective data from TEDDY effectively demonstrate the utility of 2-tiered screening and constitute a step forward in devising a population-screening strategy that best offers the appropriate treatment at a stage in life where it may yield the most lifelong benefit," writes Richard J. Noel, MD, PhD, from Duke University Medical Center in Durham, North Carolina, in an accompanying commentary in Pediatrics.
Dr Verma believes the study from Sweden advances the conversation, but does not take the concept of screening far enough. "I am glad that at least someone is thinking about screening people early," Dr Verma said. "[but] if you are between 2 and 3 years of age, you should just have a celiac panel done." She emphasized again that there are many atypical symptoms of CD, especially in children.
Genetic Risk Factors
The 2-tiered screening test may not yet be realistic for the United States.
Currently, children in the United States may be targeted for screening because they have a family history of CD or have Down syndrome, Turner syndrome, or Williams syndrome. The 2004 consensus guidelines from the National Institutes of Health indicate that patients with type 1 diabetes should also be screened for CD.
Although individuals who are homozygotic for HLA-DR3-DQ2 are at highest genetic risk for CD and tend to develop CD very early in life, HLA tests are not routinely performed in the United States, and therefore HLA status rarely triggers a CD test. According to Dr Weir, this is an evolving issue.
"Screening high-risk groups (such as family members or patients with predisposing conditions) for [CD] with serologic testing (tissue transglutaminase [immunoglobulin G and total immunoglobulin A] is widely accepted. However, in the USA, the use of HLA typing in screening children to identify who is at higher risk of [CD] has not been fully evaluated and is not currently recommended. However, as our understanding of the HLA typing and [CD] risk deepens, and as HLA testing becomes cheaper and more readily available, this may change," Dr Weir noted.
The genetic basis of CD does mean that a diagnosis of CD has implications for the entire family. If a child tests positive for CD, the family (siblings, parents, and grandparents) should be tested for CD. In addition, siblings should be periodically retested to look for the development of CD.
Poor Growth May Point to CD
Another newly proposed screening strategy suggests children should be tested for CD if they have poor growth. Although CD does not always affect growth, most children who are diagnosed experience a decrease or slowing of growth before diagnosis. A new study suggests these children could be diagnosed earlier if they were being followed in a well-established growth-monitoring program.
Antti Saari, MD, from the University of Eastern Finland in Kuopio, and colleagues published the results of their longitudinal retrospective study on the relationship between growth and CD online March 2 and in the March issue of JAMA Pediatrics. They propose that screening for CD would include the use of several growth-monitoring parameters in combination. Furthermore, the parameters should be integrated into a computerized screening algorithm associated with an electronic health record system.
"I have sort of mixed feelings about [the study].... I am personally of the belief that there should be mass screening of people," stated Dr Verma. She explained that because not all of the children with CD have growth issues, the approach proposed by Dr Saari and colleagues would miss many children with CD.
Atypical Symptoms
Dr Verma described some of the atypical symptoms of CD. For example, anemia may be a sign of CD. As a consequence, Dr Verma recommends that children with unexplained anemia be tested for CD.
She added that chronic headaches, seizures, chronic constipation, elevated liver enzymes, chronic pancreatitis, alopecia, and tiredness can all be signs and symptoms of CD. Moreover, many patients who are originally diagnosed with irritable bowel syndrome are ultimately diagnosed with CD.
Parents should be counseled to have the blood work done before experimenting with a gluten-free diet. A gluten-free diet will eventually lower the levels of antibodies, thereby making the celiac panel unreliable. Moreover, physicians should keep in mind that children who consume low levels of gluten or consume occasional gluten may have lower antibody levels, even though they have CD.
A patient who tests positive on the celiac panel should be referred to a gastroenterologist. The gastroenterologist can decide whether endoscopy is required and can counsel the patient on the importance of a gluten-free diet. Patients must understand that the gluten-free diet is for life, and they need encouragement to adopt a gluten-free lifestyle.
The authors, Dr Verma, Dr Weir, and Dr Mohammed have disclosed no relevant financial relationships.
Am J Gastroenterol. 2015;110:455-461. Choung abstract
Pediatrics. Published online March 2, 1015. Agardh full text, Commentary full text
JAMA Pediatr. Published online March 2, 2015. Abstract

The Association Between Breastfeeding and Childhood Obesity: A Meta-analysis



Jing Yan; Lin Liu; Yun Zhu; Guowei Huang; Peizhong Peter Wang
BMC Public Health. 2014;14(1267) 

Abstract and Introduction

Abstract

Background The increase in childhood obesity is a serious public health concern. Several studies have indicated that breastfed children have a lower risk of childhood obesity than those who were not breastfed, while other studies have provided conflicting evidence. The objective of this meta-analysis was to investigate the association between breastfeeding and the risk of childhood obesity.
Methods The PubMed, EMBASE and CINAHL Plus with Full Text databases were systematically searched from start date to 1st August 2014. Based on the meta-analysis, pooled adjusted odds ratio (AOR) and 95% confidence interval (CI) were calculated. I2 statistic was used to evaluate the between-study heterogeneity. Funnel plots and Fail-safe N were used to assess publication bias and reliability of results, and results from both Egger test and Begg test were reported.
Results Twenty-five studies with a total of 226,508 participants were included in this meta-analysis. The studies' publication dates ranged from 1997 to 2014, and they examined the population of 12 countries. Results showed that breastfeeding was associated with a significantly reduced risk of obesity in children (AOR = 0.78; 95% CI: 0.74, 0.81). Categorical analysis of 17 studies revealed a dose-response effect between breastfeeding duration and reduced risk of childhood obesity.

Conclusion Results of our meta-analysis suggest that breastfeeding is a significant protective factor against obesity in children.

Δευτέρα 13 Απριλίου 2015

Severe Colic Mimicking Intussusception: A New Phenomenon


Mohamed Amin El-Gohary
BMJ Open Gastro. 2015;2(1) 

Abstract and Introduction

Abstract

Objective To highlight a new phenomenon that we have encountered in children during the past 5 years. Children in this group have a pathognomonic clinical picture of sudden acute severe abdominal colic during which the child is continuously screaming for 1–2 min. All these patients were initially diagnosed on clinical and ultrasonographic grounds as acute intussusception. Careful interpretation of the radiological findings revealed faecal impaction of the terminal ileum and caecum.
Design This is a retrospective study looking at children presenting between 2009 and 2014 with acute severe abdominal colic pain. These were 11 patients aged 9 months to 5 years. We reviewed our experience in the management and diagnosis of these patients.
Result All patients were diagnosed initially as intussusception, which was confirmed by ultrasonography (US). US revealed an appearance mimicking intussusception, 3 cases of which were intermittent. This US appearance proved to be a hard stool filling the terminal ileum. In all patients, abdominal X-ray revealed stool at the right side of the colon filling the caecum. Diagnostic gastrografin enemas that were performed in four patients excluded intussusception and confirmed stool at the caecum and ascending colon. In none of those patients had contrast passed into the terminal ileum. There was dramatic response to fleet and/or gastrografin enemas. Five patients required a second dose of enema and two patients required three doses.
Conclusions We highlight a new phenomenon of severe abdominal pain caused by faecal impaction of the terminal ileum and caecum. Increased awareness of this condition helps to avoid unnecessary investigations and/or surgical exploration.

Introduction


Abdominal pain and/or colic are common symptoms in the paediatric age group, the causes of which depend on age and associated symptoms. In the past, intussusception remained the primary cause of abdominal colic in children below 2 years of age. Constipation is known to be associated with abdominal pain, but has not been known to be severe enough to warrant urgent attention. All the patients in this report presented with sudden recurrent severe colicky abdominal pain, during which they screamed in agony for 1–2 min, with the pain ending abruptly. We have learned from earlier experience with similar cases to be cautious in labelling these types of cases as intussusception and to treat them conservatively with enemas.

Παρασκευή 13 Μαρτίου 2015

Mythbusters: Does This Cause Cancer?


Victoria Stern, MA
March 04, 2015
Editor's Note: Although cancer incidence and mortality have decreased in recent years, cancer remains the second leading cause of death in the United States. According to the American Cancer Society, there were about 1,665,540 newly diagnosed cancers and 585,720 deaths in 2014.
The American Cancer Society estimates that environmental factors account for about 75%-80% of cancer cases and deaths in the United States, whereas hereditary factors make up the rest. Although most environmental risks can be attributed to lifestyle factors, such as smoking (30%) and a mixture of poor nutrition, physical inactivity, and obesity (35%), there is still a significant burden from a range of environmental exposures. The International Agency for Research on Cancer (IARC), the World Health Organization's cancer research division, has classified 107 such agents to be carcinogenic to humans; these include tobacco, asbestos, benzene, arsenic, ionizing radiation, and ultraviolet radiation.
But for other environmental exposures or chemicals, the link to cancer remains less clear. In this column, Medscape has investigated five common concerns that people have about environmental cancer risks to determine how robust the link to cancer actually is.

Does BPA Increase Cancer Risk?

What the science says: Determining whether a link between bisphenol A (BPA) and cancer exists has become increasingly important, given the ubiquity of this substance. BPA, which forms the building blocks of polycarbonate plastics and resins, has become one of the highest-volume chemicals produced worldwide. The compound is found in a range of consumer goods, including baby and water bottles, eyeglass lenses, toys, cell phones, and food containers, as well as in the lining of most food and beverage cans. Research from the Centers for Disease Control and Prevention shows that more than 90% of Americans have BPA in their urine,[1]probably because the chemical can leach from bottles and cans.[2,3]
Inquiry into the health effects of synthetic estrogens and other endocrine disruptors began in the late 1960s, when seven young women in Massachusetts were diagnosed with a very rare cancer: clear cell adenocarcinoma of the vagina. This grouping of rare cancers motivated doctors at Massachusetts General Hospital to try to identify a common cause. After an in-depth analysis, the doctors traced the source of the cancer to diethylstilbestrol (DES), a potent synthetic estrogen commonly given to pregnant women because it was thought to help prevent miscarriages. The doctors published their findings in the New England Journal of Medicine in 1971,[4]and shortly thereafter the US Food and Drug Administration (FDA) advised physicians to stop giving DES to pregnant women because of the strong link to cancer.
This initial work spurred scientists to take a closer look at the effects of DES and other endocrine disruptors, such as BPA, on the health of humans and animals. In 1991, experts from an array of disciplines gathered at the Wingspread Conference on the Precautionary Principle to discuss a growing body of evidence pointing to the harmful effects of chemical exposures on human and animal populations. The attendees issued a consensus statement: "We are certain of the following: a large number of man-made chemicals that have been released into the environment, as well as a few natural ones, have the potential to disrupt the endocrine system of animals, including humans."[5]
In 2009, given the weight of the research, the Endocrine Society also issued a scientific statement on the health effects of endocrine disruptors[6]: "Results from animal models, human clinical observations, and epidemiological studies converge to implicate [endocrine-disrupting chemicals] as a significant concern to public health."
In 2010, Ana M. Soto, MD, and Carlos Sonnenschein, MD, biologists at Tufts University School of Medicine in Boston, published a review in Nature Reviews Endocrinology evaluating 30 years' worth of research on whether endocrine disruptors increase the risk of developing breast and prostate cancer.[7] Studies showed, for example, that when pregnant rats are exposed to low doses of BPA, their offspring are more likely to develop precancerous mammary lesions in adulthood.[8] In addition, studies have reported that infant rats exposed to BPA during lactation and treated with a chemical carcinogen at 50 days of age displayed an elevated risk of developing mammary tumors in adulthood compared with animals not exposed to BPA while nursing.[9] Overall, the authors concluded that "Sufficient supporting data have been gathered on the deleterious effects of endocrine disrupting chemicals to warrant immediate action to decrease human and wildlife exposure to these agents."
A subsequent review published in 2013 by Dr Soto and colleagues continued to support previous findings.[10] The growing body of research uncovered compelling evidence that fetal and neonatal BPA exposure in rats increased the risk for mammary cancer later in life. The authors concluded that these data in laboratory animals can probably be extrapolated to humans and that exposure to BPA and other endocrine-disrupting chemicals has probably contributed "to the increase in the incidence of breast cancer observed over recent decades."
Experts have also proposed several possible mechanisms to explain a link between BPA and cancer. A 2012 study found that BPA can promote human breast cancer cell growth,[11] and a 2014 study revealed that fetal exposure to BPA in rats alters the expression of genes that regulate the cell cycle, which in turn may increase the likelihood of developing tumors.[12] The 2014 study also showed that BPA increases the incidence of cancerous lesions in adult rat mammary glands. Another 2014 study found that significantly more mice implanted with human prostate stem cells developed precancerous or cancerous lesions later in life after being exposed to low doses of BPA compared with those who were not exposed.[13] Another theory posits that cancer is due to altered tissue organization, a view that is gaining acceptance and that may better explain a link between BPA and cancer, according to Dr Soto.
Aside from a link to cancer, research also suggests that BPA can promote a range of other health issues, including heart disease, diabetes, obesity, and infertility.[14-16]
Despite the mounting evidence in animal models, a causal link between BPA and cancer risk in humans has not been confirmed. According to the World Health Organization's 2014 World Cancer Report, "Definitive proof of the role of BPA in human cancer induction is likely to remain limited, not least by ethical limits to human experiments."
What the expert says: According to Dr Soto, "If we take the results in animal models together, I think we have enough evidence to conclude that BPA increases the risk for breast and prostate cancer in humans."
Still, uncovering a causal link between BPA exposure and cancer in humans is essentially impossible. "To expose humans on purpose is unethical, so there is a limit to what we can investigate," Dr Soto said. In addition, because almost everyone is exposed to BPA, it would not be feasible to conduct a human study comparing the health effects of BPA in people who are exposed vs those who are not.
"In such a case, we need to extrapolate to humans, because to wait for conclusive evidence in humans would be criminal," Dr Soto said. "Given the strong evidence in rats and mice, it is very likely that humans experience similar effects, because we share the same hormones and receptors."
Dr Soto added, "At some point, we have to question how much knowledge is enough to warrant action. To me, we've passed the point with BPA."
To reduce exposure, Dr Soto recommends avoiding plastics that could contain BPA. "The problem here is that we do not know exactly how pervasive BPA is." For instance, polycarbonate is often used for industrial filtering, so drinking from a glass bottle does not necessarily mean the liquid is BPA-free.
"What we really need is global legislation," Dr Soto said. Lawmakers in France and Denmark have already implemented a policy to ban BPA from all food packaging. Until such regulations are instituted in more countries worldwide, Dr Soto advises people to talk to their local representatives and to take part in the public debate.
Verdict: Plausible to likely, given strong evidence in animal models.

Can Cell Phones Increase Risk for Brain Cancer?

What the science says: Despite 20 years of research investigating a link between mobile phone use and brain cancer, experts remain polarized on the issue. Some assert that an increased risk is unlikely, given that the rates of brain cancer haven't risen significantly enough in the past few decades and that cell phones don't give off powerful enough radiation to damage DNA, whereas others believe that studies at the epidemiologic and cellular levels show convincing evidence of an increased risk and point to data that do show a notable increase in the rate of brain cancer.
During the past two decades, the use of mobile phones has skyrocketed. The International Telecommunication Union estimates that worldwide subscriptions reached almost 7 billion at the end of 2014, making it more pertinent than ever to resolve the debate.
Public concern can be traced to the early days of cell phones. In 1992, David Reynard filed a tort claim against the cell phone manufacturer NEC—the first claim of its kind in the United States—because he believed that his wife, Susan, had developed (and later died of) a brain tumor from using her cell phone. The courts rejected the claim owing to "uncertainty of the evidence," but the investigation helped reveal an important gap in our understanding of the effect cell phones may have on our biology.
As Siddhartha Mukherjee, MD, PhD, assistant professor of medicine in the Division of Medical Oncology at Columbia University and author of The Emperor of All Maladies: A Biography of Cancer, has explained, one of the most difficult challenges in cancer epidemiology is unraveling the relationship between a common exposure, such as cell phones, and a rare form of cancer.
One of the methods of disentangling this relationship is case/control studies, which compare people with and without brain cancer through the lens of their cell phone use. Such epidemiologic studies, however, have not yielded totally consistent results.
In a 2009 article, Michael Kundi, PhD, head of the Institute of Environmental Health of the Medical University of Vienna, reviewed 25 case/control studies conducted in the past 10 years that explored a link between cell phone use and brain tumor risk, two of which evaluated participants for more than 10 years.[17] Overall, Dr Kundi found an increased risk for glioma and acoustic neuroma, but some of the individual study results varied. For instance, a 2005 case/control study found that cell phone use was associated with a decreased risk for high-grade glioma, implying a protective effect, and no elevated risk for low-grade glioma or meningioma,[18] but case/control studies by Lennart Hardell, MD, PhD, an oncologist and professor in the Department of Oncology, University Hospital, Örebro, Sweden, have consistently revealed a significantly increased risk of developing acoustic neuroma, glioma, or meningioma in people using mobile phones for more than 10 years.[19,20]
Dr Kundi concluded his review cautiously, stating that epidemiologic evidence "starts to indicate an increased risk, in particular for brain tumors." He also noted that from a public health standpoint, an increase in brain tumor incidence is problematic, but from an individual perspective, the risk remains low.
In 2010, results of the long-awaited Interphone study—the largest case/control study to date exploring the link between cancer and cell phones—were published.[21]Experts hoped the Interphone study would clarify inconsistencies in the literature, but it seemed to complicate matters further. The study involved researchers from 13 countries over 10 years and included 5117 brain tumor cases and 5634 controls. The authors reported a reduced risk for glioma and meningioma in regular cell phone users, but an elevated risk for glioma in people reporting the greatest exposure to cell phones.
Overall, the Interphone results indicated a systemic flaw in the trial, according to Dr Mukherjee, who wrote in a New York Times article that "it is biologically implausible that these results are simultaneously true: how can regular cell phone use protect against cancer while frequent phone use increases risk?"
In addition, when the study's supplementary data—which were not included in the main results—are examined, a more complex picture emerges. For instance, regular cell phone users displayed a greater risk for glioma on the side of the face where they held their phone.
A 2014 report from Dr Hardell's group, which pooled results from two case/control studies on malignant brain tumors diagnosed from 1997 to 2003 and from 2007 to 2009, found that both mobile and cordless phone use significantly elevated the risk for glioma, especially for people who had used their phones for over 25 years.[22]
Aside from case/control studies, animal and genetic studies represent important avenues of inquiry. Cell phones emit nonionizing radiation, which, unlike ionizing radiation, is not energetic enough to directly cause DNA damage. Cell phones emit radiofrequency energy that typically falls in the range of 450-2700MHz, which is powerful enough to trigger chemical reactions. Research exploring the effects of such radiofrequencies in laboratory animals has generally not supported a link to cancer specifically,[23] yet some studies have indicated that these frequencies are powerful enough to damage brain cells in rats.[24]
The effects of radiofrequency energy, however, may be subtler than can be gleaned from animal studies. The energy from mobile phones may leave an imprint on our cells in ways that indirectly lead to tumors down the road—for instance, by decreasing production of a protein known to protect against cancer or by altering brain chemistry in small but notable ways.
For instance, in a 2011 study published in JAMA, Nora Volkow, MD, a brain researcher and director of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues attempted to determine whether radiofrequency energy could alter brain activity by placing cell phones next to the ears of 47 participants.[25] Dr Volkow found that just 50 minutes of exposure to an activated cell phone, compared with a deactivated one, increased glucose metabolism in the brain regions closest to the antenna. The investigators concluded that although the study does not provide information regarding potential carcinogenic effects from cell phone use, it does reveal that exposure to cell phones can affect brain function in humans.
Similarly, researchers have found that cell phone radiation can cause numerous changes on the cellular level, but it's unclear whether these changes can be extrapolated to cancer risk in humans.[26] Several studies, for instance, have shown radiation levels from cell phones can alter the structure of chromatin—a complex of DNA and proteins that helps regulate gene expression and prevent DNA damage—but others cannot confirm whether these changes have an impact on cancer risk.[27-29]
What the experts say: According to Véronique Terrasse, a spokesperson for IARC, the cancer research branch of WHO, the agency classifies the radiofrequency electromagnetic fields produced by mobile phones as possibly carcinogenic to humans, on the basis of both epidemiologic and animal studies. The category is considered "group 2B," which means a causal association is considered credible, but chance, bias, or confounding cannot be ruled out.
David Carpenter, MD, a professor of environmental health sciences at the University at Albany, State University of New York, would change the IARC's classification to "likely."
"Studies evaluating individuals who have used cell phones for 10 years or more consistently show that they are more likely to develop a glioma," Dr Carpenter said. Given that brain tumors are slow-growing, "we do not yet know the very long-term effects of energy emissions from cell phones, but the trends suggest that our risk increases the longer we use them."
Denis Henshaw, PhD, emeritus professor and senior research fellow in chemistry (now retired) at the University of Bristol, United Kingdom, agreed with Dr Carpenter that research suggests the link between cell phone use and brain tumor risk is credible, especially for prolonged use. "Although the risk for brain tumors in the individual is small, even a doubling of risk from prolonged mobile phone use is of public health significance. I think that the IARC classification should be elevated to 2A (probable carcinogen)."
Leeka Kheifets, PhD, professor of epidemiology in the University of California, Los Angeles, School of Public Health, thinks that the IARC's characterization of the cell phone cancer risk is probably correct, given the current evidence. "It doesn't look like cell phone use is a major risk factor for brain cancer in adults, which is fairly reassuring," Dr Kheifets said.
Until there is further evidence, it may be wise to err on the side of caution. "This is not something people should freak out about, but there are simple ways to reduce exposure to cell phones, such as using headsets or landlines," Dr Carpenter said. "Limiting exposure is especially important, considering that we encounter a range of radiofrequency fields in our daily lives—from our computer, WiFi signal, and commonly used household appliances, such as microwaves."
Verdict: Plausible. The evidence is mixed, with considerable debate and uncertainty in the field.
Editor's Note: An earlier version of this article suggested the connection between cell phone use and cancer was "compelling"; it now more accurately reflects the inconclusive state of the science.

Can Artificial Sweeteners Cause Cancer?"

What the science says: Fears about the potential carcinogenic effects of artificial sweeteners continue to persist, despite a compelling body of evidence showing that no such link exists.
Concerns emerged more than 40 years ago, after studies indicated that the artificial sweetener cyclamate might be linked to cancer, prompting the FDA to ban its use. These findings also compelled researchers to investigate the potential carcinogenesis of another popular artificial sweetener, saccharin.
In 1977, a study published in Science found an association between saccharin and bladder cancer in rats,[30] spurring the FDA to ban saccharin as well. The FDA lifted the ban, however, after thousands of people wrote letters of protest. But until concerns about saccharin could be resolved, the FDA maintained that all foods containing the sweetener must have a warning label stating that "Use of this product may be hazardous to your health. This product contains saccharin, which has been determined to cause cancer in laboratory animals."
Subsequent studies in rats continued to show an elevated risk for bladder cancer after the animals consumed very high doses of the sugar substitute,[31,32] but results in humans showed no clear evidence of an association.[33] In fact, experts soon found that the mechanism that led to cancers in rats was irrelevant in humans.[34]Specifically, when consumed in high doses, researchers discovered that saccharin changes the composition of rat urine, creating a precipitate. The precipitate can damage the cells lining the bladder, which in turn can promote tumor growth when the cells regenerate. This mechanism, however, is unique to rats.
In a monograph published in the late 1990s, a group of experts at the IARC analyzed the results of 17 case/control studies exploring the link between saccharin and bladder cancer in humans. The IARC concluded that "there is inadequate evidence [emphasis original] in humans for the carcinogenicity of saccharin salts used as sweeteners" and downgraded its original categorization of group 2B (possibly carcinogenic to humans) to group 3 (not classifiable as carcinogenic to humans).
In 2000, the National Toxicology Program of the National Institutes of Health removed saccharin from the list of potential carcinogens. In addition, further studies in humans have continued to find no evidence of a link between saccharin consumption and cancer risk.[35]
The data on the carcinogenic effects of other artificial sweeteners, such as aspartame, have formed the basis for similar conclusions. In 2006, researchers at the National Cancer Institute prospectively investigated the link between aspartame consumption and the risk for malignant brain cancer in 285,079 men and 188,905 women who were part of the NIH-AARP Diet and Health Study of retirees.[36]
Over 5 years, the researchers identified 1888 hematopoietic cancers and 315 malignant gliomas and found that higher levels of aspartame were not associated with an elevated risk for either cancer or their subtypes in both men and women. The authors concluded that their findings "do not support the hypothesis that aspartame increases hematopoietic or brain cancer risk."
In the past 10 years, newer-generation artificial sweeteners, including acesulfame potassium (ACK, Sweet One®, Sunett®), sucralose (Splenda®), and neotame (Newtame®), have become widely available. But before these sweeteners received FDA approval, the FDA performed more than 100 safety studies on each one. According to the National Cancer Institute, "The results of these studies showed no evidence that these sweeteners cause cancer or pose any other threat to human health."
What the expert says: "Although there has been a lot of negative press about artificial sweeteners, there is no evidence that artificial sweeteners cause cancer in humans," said Christine Zoumas, MS, RD, project manager of the Diet and Physical Activity Shared Resource at the University of California, San Diego, Moores Cancer Center.
When a food or color additive is developed, Ms Zoumas explained, it goes through dozens of toxicity, animal, and human studies before being approved. Aspartame, for instance, was first developed in 1965 but wasn't FDA approved until 1981, after undergoing testing for 16 years. Even then, the sweetener was only permitted as an additive in selected products while researchers continued to monitor its effects.
The FDA also establishes an acceptable daily intake for additives—the amount of a product a person can safely consume each day with no side effects, Ms Zoumas noted. For aspartame, for instance, the acceptable daily intake is 50 mg/kg of body weight. That means a 60-kg person can safely consume 3000 mg of aspartame per day, which is equivalent to about 136 packets of Equal or sixteen 12-ounce cans of diet soda.
"The testing for food additives in the United States is very rigorous," Ms Zoumas said. "If there was indeed a link between artificial sweeteners and cancer, these products would be off the shelves."
Verdict: No link.

Do Pesticides Increase Cancer Risk?

What the science says: The relationship between pesticide exposure and cancer risk remains difficult to discern. Farmers and others in the agricultural workforce tend to have lower cancer rates overall, which is largely attributed to their physically active lifestyles and lower smoking rates.[37] Still, certain cancers—primarily lymphoma, multiple myeloma, and prostate cancer—occur in higher frequencies in this population.[38]
Some experts surmise that exposure to pesticides and other chemicals may be a strong contributor to the elevated rates of these specific cancers. Recent data from the Agricultural Health Study (AHS), the longest-running prospective cohort study exploring a potential link between pesticides and cancer, supports evidence of an elevated risk for some cancers, but not for others.[39] After following more than 84,000 pesticide applicators and their wives in Iowa and North Carolina from 1993 to 2006, the researchers reported a significantly lower incidence of cancer overall—specifically for oral, colon, lung, bladder, and kidney cancer—compared with the general populations of those states. But the researchers did find an elevated risk for a range of other cancers, including multiple myeloma, prostate cancer, lip cancer, and certain subtypes of non-Hodgkin lymphoma.
In a follow-up study, the AHS group tried to determine the risk for prostate cancer associated with specific pesticides. The 2013 study published in the American Journal of Epidemiology revealed that four insecticides—fonofos, malathion, terbufos, and aldrin—were associated with significantly increased risk for aggressive prostate cancer in farmers and commercial pesticide applicators.[40]
Two subsequent studies from the AHS group found associations between several commonly used pesticides and an elevated risk for specific cancers. One study reported an association between the pesticides DDT, lindane, permethrin, diazinon, and terbufos and certain subtypes of non-Hodgkin lymphoma,[41] whereas another study reported an elevated risk for colorectal and lung cancer risk in the AHS cohort exposed to acetochlor.[42] The authors of the acetochlor study arrived at a cautious conclusion, however, stating that "due to lack of exposure-response trend, small number of exposed cases, and relatively short time between acetochlor use and cancer development, these findings warrant caution in interpretation and further investigation."
Yet other studies have revealed no discernable link between certain pesticides and cancer risk. A 2012 review of epidemiologic studies did not find evidence of increased cancer risk in people exposed to the popular herbicide glyphosate,[43] and a 2013 review of epidemiologic evidence examining a link between atrazine and cancer risk concluded that "there is no causal association between atrazine and cancer and that occasional positive results can be attributed to bias or chance."[44]
What the experts say: According to Paolo Boffetta, MD, MPH, director of the Institute for Translational Epidemiology and professor in the Division of Hematology and Medical Oncology and the Department of Preventive Medicine at Mount Sinai School of Medicine, "For those with high pesticide exposure levels, the link is very plausible for some cancers, such as lymphoma or myeloma and possibly prostate cancer as well. But for other cancers, I don't think evidence is very strong. For consumers, the low level of exposure probably does not increase cancer risk."
The link between pesticides and cancer risk is complex. All pesticides are tested for general toxicity, and most linked to cancer in animals have been banned. "What we have left are chemicals that do not show an effect in animal models," Dr Boffetta said.
In addition, it is difficult to study the effects of individual pesticides in humans. For instance, farmers and applicators apply a range of chemicals in different combinations, and thus are exposed to many agents over time. "It becomes very challenging to identify people exposed to only one pesticide, and it is therefore difficult to identify which individual pesticide or chemicals may put people at risk," Dr Boffetta said. "I don't think for any specific agent, we can state that there is conclusive evidence it causes cancer, but some studies do show an elevated risk for cancer in those with significant pesticide exposure."
Although Dr Boffetta believes further research is needed to determine a causal link, he thinks it is important to reduce exposure levels overall. "I would recommend lowering exposure where possible, especially for applicators and farmers. For consumers, it may be worth erring on the side of caution, even though their risk is likely to be very low."
Ms Zoumas noted that in consumers, there is no clear association between pesticide exposure and cancer risk. "There does not appear to be a benefit of organic produce," Ms Zoumas said. "It may be more important to wash fruit well and to be careful about specific fruits, known as the 'dirty dozen,' that have higher levels of pesticides."
Verdict: Plausible in people with high exposure levels (farmers and pesticide applicators), but unlikely in consumers with very low levels of exposure.

Do Extremely Low-Frequency Magnetic Fields From Power Lines Increase Cancer Risk?

What the science says: Almost 30 years ago, a study published in the American Journal of Epidemiology reported a higher risk for leukemia in children who lived near power lines.[45] The authors suggested a possible explanation for this could be magnetic fields, sparking concern that emissions from power lines could cause cancer.
Power lines expose people to extremely low-frequency magnetic fields (ELF MFs) generally within the 50- to 60-Hz range. These fields are even less energetic than the nonionizing radiation produced by cell phones. Given the low levels of radiation emitted, ELF MFs have been generally perceived to be harmless.
But after decades of investigation, epidemiologic studies have consistently found associations between ELF MFs at relatively high levels and childhood leukemia. A meta-analysis published in 2000 examined the results of nine studies to determine whether an association between magnetic fields and childhood leukemia did indeed exist.[46] The researchers found that 99.2% of children living with exposure levels below 0.4 microtesla (μT) showed no increased risk, but the 0.8% of children with exposures of 0.4 μT or more had an elevated risk. A second meta-analysis, which pooled data from 15 studies, found that exposure to ELF MFs of at least 0.3 μT was associated with an almost twofold increased risk for childhood leukemia.[47] To put this risk into context, about 1 in 20,000 US children per year is at risk for leukemia, and proximity to a power line may double those odds to 2 in 20,000 per year, according to statistics from the Centers for Disease Control and Prevention.
In 2002, the IARC classified ELF MFs as possibly carcinogenic to humans on the basis of studies of childhood leukemia (group 2B), because the large body of epidemiologic evidence consistently shows an association between ELF MFs and childhood leukemia; however, the mechanism for how ELF MFs could cause childhood leukemia is still not understood. In addition, no animal model for childhood leukemia exists, making the association difficult to study in animals. Such models have been developed only recently, but they have not yet been tested.
After 2002, subsequent epidemiologic analyses have continued to find an association between ELF MFs and childhood leukemia. In a 2010 analysis, Dr Kheifets and colleagues pooled seven studies performed after 2000, which included 10,865 cases and 12,853 controls.[48] In most individual studies and in the combined results, the risk for childhood leukemia increased with greater exposure, but the association was weaker in the most recently conducted studies. Dr Kheifets and her colleagues concluded, "Our results are in line with previous pooled analyses showing an association between magnetic fields and childhood leukemia."
Still, causality remains uncertain. A 2013 literature review aimed to estimate the cases of childhood leukemia that might be attributable to ELF MF exposure in the European Union, if the association were indeed causal.[49] The researchers mapped out several exposure/response scenarios and estimated that about 50-60 cases of childhood leukemia could be attributed to ELF MF exposure, depending on the model used. This estimate corresponded to about 1.5%-2.0% of all cases of childhood leukemia. The authors concluded that "according to the current state of evidence, residential exposure to ELF MF may contribute to cases of leukemia in children, but this contribution is relatively small and is characterized by considerable uncertainty."
According to the National Cancer Institute, "Overall, these [epidemiologic] analyses suggest that if there is any increase in leukemia risk from magnetic fields, it is restricted to children with the very highest exposure levels."
Regarding a potential mechanism, a 2011 study found that exposure to 50-Hz magnetic fields at 100 µT increased genotoxicity in a human tumor cell line, but also found the rate of DNA repair increased in exposed cells.[50] A subsequent 2014 study from the same group identified cellular changes induced in a human tumor cell line exposed to a 50-Hz magnetic field for 24 hours.[51] Overall, the exposure disturbed the balance in the cell and increased production of chemically reactive molecules. Although the exposure levels in these studies are orders of magnitude above those used in epidemiologic studies, they do start to hint at how magnetic fields may alter cellular activity and potentially induce genomic instability.
What the experts say: "There is consistent epidemiologic evidence for such an association, but support for causality is missing from experimental research," Martin Röösli, PhD, head of the Environmental Exposures and Health Unit, Swiss Tropical and Public Health Institute, Associated Institute of the University of Basel, Switzerland, told Medscape in an email.
According to Dr Kheifets, "Research in this area indicates that there is no increased risk for major cancers, such as breast cancer, from ELF MFs." But, she said, the evidence that remains unresolved is the link to childhood leukemia. "The epidemiologic studies have consistently found an association between childhood leukemia and magnetic fields, but a plausible explanation for this association is lacking—which means it could be due to chance, bias, or other (yet to be identified) factors related to both magnetic fields and childhood leukemia, or it could be a true association. Even if we were to confirm a relationship between ELF MFs and childhood leukemia, the risk appears to be very low."
Dr Henshaw, however, believes that the link to childhood leukemia is a robust one. "When we come to cellular studies, there is extensive evidence of DNA damage in cells exposed to magnetic fields. For instance, recent work shows that low-level MFs can increase the rate at which free radicals are produced in the cell."
Dr Kheifets noted that it's important to resolve this issue, because any factor that may raise the risk for childhood leukemia is important to understand. "What we need now are some novel approaches to really understand the association."
Verdict: Uncertain, according to Dr Kheifets. Very likely, according to Dr Henshaw. The evidence is highly consistent for an increased risk for childhood leukemia at higher-intensity ELF MFs, but a precise mechanism and animal models for leukemia are still needed.